ALX Oncology (ALXO) Corporate presentation summary
Event summary combining transcript, slides, and related documents.
Corporate presentation summary
16 Nov, 2026Strategy and catalysts
Two programs, evorpacept and ALX2004, target multiple development inflection points in 2026–2027.
ASPEN-09 is enrolling 120 patients with HER2+ metastatic breast cancer after ENHERTU; topline data are anticipated in 2H 2027.
ALX2004 Phase 1 safety and early efficacy results from approximately 40 patients are expected in December 2026.
Evorpacept clinical evidence
In ASPEN-06 retained HER2+ gastric cancer, CD47-high patients had ORR of 65% with evorpacept plus trastuzumab, ramucirumab and paclitaxel versus 26.1% with control.
ASPEN-06 CD47-high patients had median PFS of 18.4 months with evorpacept combination versus 7.0 months with control; HR 0.39 (95% CI 0.17–0.86).
In HER2+ breast cancer, CD47-high patients receiving evorpacept plus zanidatamab had median PFS of 22.1 months versus 3.4 months in CD47-low patients.
ASPEN-06 showed comparable any-cause adverse-event incidence between arms; evorpacept has been studied in >750 patients, with a generally manageable and reversible safety profile.
ALX2004 development
ALX2004 is an EGFR-targeted ADC with a matuzumab-derived antibody, proprietary linker and DAR 8 topoisomerase I inhibitor payload.
Preclinical studies reported dose-dependent activity across tumors and EGFR levels; NHP studies found no evidence of ILD or major dose-limiting target-organ toxicity.
Phase 1 dose escalation is evaluating EGFR-expressing NSCLC, HNSCC, CRC and ESCC; expansion could assess selected tumor types and dose schedules.
Latest events from ALX Oncology
- Cash runway through H1 2028; evorpacept and ALX2004 data catalysts ahead.ALXO
Q3 2026 - Lead assets advance toward phase III, with strong biomarker focus and robust financial runway.ALXO
H.C. Wainwright 28th Annual Global Investment Conference - Biomarker-driven CD47 and novel EGFR ADC programs show promise for hard-to-treat cancers.ALXO
12th Annual Cantor Fitzgerald Global Healthcare Conference - ALX2004 and evorpacept advance toward registrational trials, targeting key oncology indications.ALXO
Wells Fargo 21st Annual Healthcare Conference - Q2 2026 net loss narrowed, expenses fell, and cash reserves support operations into 2028.ALXO
Q2 2026 - First randomized CD47 solid tumor trial shows strong efficacy, fueling expansion and partnership talks.ALXO
2024 Cantor Fitzgerald Global Healthcare Conference - Two high-value oncology programs advance toward pivotal data with strong financial support.ALXO
Jefferies London Healthcare Conference 2025 - Evorpacept plus PADCEV achieved a 59–62% response rate with favorable safety in advanced bladder cancer.ALXO
Study Update - Evorpacept advances in pivotal trials, extends cash runway, and prepares new ADC for the clinic.ALXO
Status Update